Global Health Diplomacy and Management Mechanisms of US-China Public Health Collaborations in China: Lessons for Emerging Markets

Authors

  • Matthew David Brown Matthew Brown is Senior Advisor, Office of Global Affairs, Department of Health and Human Services, and a PhD student in the Joint Doctoral Program in Global Health at San Diego State University – University of California, San Diego.

DOI:

https://doi.org/10.5912/jcb569

Keywords:

Emerging markets, China, health diplomacy, health management, program planning, global health

Abstract

China is the largest emerging market in the world. It is also on the front lines of health diplomacy, where the tools of diplomatic statecraft are being employed by public health professions of both the US and China to help improve the practice of public health. This article examines the US Department of Health and Human Services’ (HHS) and the US Centers for Control and Prevention (US CDC) in China, describes critical features of the Chinese health system, presents two examples of US-China collaborations, and describes common management mechanisms and strategies supporting both. This examination will help inform other global health collaborations between the US and China as well as lessons for supporting global health collaborations in other middle income countries.

References

Campbell D, Chui M. (2010) Pharmerging shake-up: New imperatives in a redefined world. imshealthcom. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Pharma_Shake-up_Imperatives_3_10.pdf, accessed 21 May 2012.

Yang, G., Kong, L., Zhao, W., Wan, X., Zhai, Y., Chen, LC. et al. (2008) Emergence of chronic non-communicable diseases in China. Lancet 372(9650):1697–705.

Gao, M. (1997) Continuing improvement in health quality of China's population. China Popul Today 14(1):17–8.

Gong, P., Liang, S., Carlton, EJ., Jiang, Q., Wu, J., Wang, L. et al. (2012) Urbanisation and health in China. Lancet 379(9818):843–52.

Pricewaterhousecoopers. (2009) Pharma 2020: Marketing the future - Which path will you take? Pharma 2020 series, http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020/pharma-2020-marketing-the-future-which-path-will-you-take.jhtml, accessed 21 May 2012.

Ma, J., Lu, M. and Quan, H. (2008) From A National, Centrally Planned Health System To A System Based On The Market: Lessons From China. Health Affairs 27(4):937–48.

Beach, M. (2001) China's rural health care gradually worsens. Lancet 358(9281):567–7.

Chinese Government. (2009) Ministry of Health. http://english.gov.cn/2005-10/09/content_75326.htm, accessed June 4, 2012.

Lu, X. and Gill, B. (2007) China’s Response to HIV/AIDS and U.S.- China Collaboration An Update from the CSIS Freeman Chair in China Studies. Center for Strategic and International Studies, http://csis.org/files/media/csis/pubs/071002-lu-gill-chinaresponsehiv4web.pdf, accessed June 4, 2012.

Lu, L., Jia, M., Ma, Y., Yang, L., Chen, Z., Ho, DD. et al. (2008) The changing face of HIV in China. Nature 455(7213):609–11.

Wu, Z., Wang, Y., Mao, Y., Sullivan, SG., Juniper, N. and Bulterys, M. (2011) The integration of multiple HIV/AIDS projects into a coordinated national programme in China. Bull. World Health Organ 89(3):227–33.

Chan, L-H., Chen, L. and Xu, J. (2010) China's Engagement with Global Health Diplomacy: Was SARS a Watershed? PLoS Med 7(4):e1000266.

Feng, Z., Li, W. and Varma, JK. (2011) Gaps Remain In China's Ability To Detect Emerging Infectious Diseases Despite Advances Since The Onset Of SARS And Avian Flu. Health Affairs 30(1):127–35.

Published

2012-10-01

Issue

Section

Special Section